Northern Trust Corp Buys 28,863 Shares of Sera Prognostics, Inc. (NASDAQ:SERA)

Northern Trust Corp boosted its stake in shares of Sera Prognostics, Inc. (NASDAQ:SERA) by 11.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 272,860 shares of the company’s stock after purchasing an additional 28,863 shares during the period. Northern Trust Corp owned about 0.81% of Sera Prognostics worth $2,221,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD bought a new position in Sera Prognostics during the fourth quarter valued at approximately $93,000. Walleye Capital LLC bought a new position in Sera Prognostics in the fourth quarter worth approximately $98,000. Wells Fargo & Company MN raised its position in Sera Prognostics by 55.2% in the fourth quarter. Wells Fargo & Company MN now owns 13,192 shares of the company’s stock worth $107,000 after acquiring an additional 4,691 shares during the period. Townsquare Capital LLC bought a new position in Sera Prognostics in the fourth quarter worth approximately $130,000. Finally, Rhumbline Advisers raised its position in Sera Prognostics by 10.6% in the fourth quarter. Rhumbline Advisers now owns 36,101 shares of the company’s stock worth $294,000 after acquiring an additional 3,468 shares during the period. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Trading Down 6.9%

SERA opened at $1.75 on Monday. Sera Prognostics, Inc. has a 1-year low of $1.70 and a 1-year high of $9.91. The company has a market capitalization of $65.93 million, a PE ratio of -1.77 and a beta of 0.99. The firm’s 50 day simple moving average is $3.08 and its two-hundred day simple moving average is $5.11.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.06 million. Equities analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.